Overview: FISH RARA Variant Panel
Introduction: The FISH RARA Variant Panel is a diagnostic tool designed to detect RARA variant translocations using whole blood or bone marrow samples. In India, acute promyelocytic leukemia (APL) variants with RARA rearrangements (e.g., t(11;17), t(5;17)) are rare (~1-2 percent of APL) but resistant to standard ATRA/ATO, requiring alternative therapy. High morbidity from under-testing in rural/low-SES APL patients with coagulopathy, limited FISH labs, delayed identification leading to treatment failure or fatal hemorrhage. Per hematology practices aligned with ICMR and Indian Society of Hematology guidelines, the test employs FISH for RARA variant translocations over 1-2 days with high sensitivity/specificity, valuable for rapid subtyping in atypical APL or ATRA-resistant cases. This diagnostic falls under genetic cancer screening and targets suspected APL with negative t(15;17) or poor response, addressing accurate detection to guide salvage regimens or trials. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise molecular diagnosis and reducing APL mortality. Its blood/bone marrow-based approach ensures reliable variant detection.
Other Names: FISH RARA Pnl.
FDA Status: FDA approved, CLIA certified for cytogenetics/oncology, compliant with 2025 standards.
Historical Milestone: RARA variant FISH for APL; in India, used in resistant APL cases.
Purpose: The test detects 2 parameters including RARA variant translocation to guide APL genetic assessment, identify non-t(15;17) variants, inform therapy.
Test Parameters: 1. RARA Variant Translocation, 2. Chromosomal Rearrangement.
Pretest Condition: No fasting required; patients should have suspected APL or ATRA resistance.
Specimen: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for FISH).
Medical History: Patients should provide details on coagulopathy, promyelocytes, prior ATRA.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected variant including treatment failure, benefits of detection, and minimal discomfort from blood/bone marrow draw.
Procedural Considerations: The test involves sample processing using FISH by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided probes/controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low blast count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive RARA variant indicates resistant APL, necessitating specialist input. Negative may require follow-up.
Specialist Consultation: Hematologists/oncologists should be consulted for management.
Additional Supporting Tests: PML/RARA PCR, NGS for confirmation.
Test Limitations: Detects variants only; comprehensive approach required.
References: Indian Journal of Hematology 2024, APL Studies India 2023.
